Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Sign Up to like & getrecommendations! Published in 2019 at "Bioorganic chemistry"
DOI: 10.1016/j.bioorg.2019.103111
Abstract: Type 2 diabetes mellitus (T2DM) is a disorder distinguished by resisting insulin effects and/or its reduced secretion leading to high blood sugar levels. It is fast becoming epidemic worldwide and is a major cause of… read more here.
Keywords: hplc; teneligliptin; method; dapagliflozin empagliflozin ... See more keywords
Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Diabetes Research"
DOI: 10.1155/2022/2420857
Abstract: Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce blood glucose, blood pressure, and body weight in patients with type 2 diabetes (T2D). However, the comparative long-term effectiveness and safety of SGLT2i among similar drugs, administered at… read more here.
Keywords: dapagliflozin empagliflozin; long term; effectiveness safety; term effectiveness ... See more keywords
Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0269414
Abstract: Background: The cardiovascular and renal benefits of sodium glucose co-transporter 2 inhibitors (SGLT2i) have been clearly demonstrated. However, studies comparing the effects of dapagliflozin and empagliflozin are scarce. Therefore, we aimed to compare the clinical… read more here.
Keywords: dapagliflozin empagliflozin; disease; group; empagliflozin patients ... See more keywords
Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s366943
Abstract: Objective Dapagliflozin 10 mg and empagliflozin 10 mg have been recommended to treat heart failure with reduced ejection fraction (HFrEF), and the purpose of this study was to compare the efficacy and safety of them… read more here.
Keywords: dapagliflozin empagliflozin; ejection fraction; heart; dapagliflozin ... See more keywords
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm13050747
Abstract: Sodium–glucose cotransporter-2 (SGLT2) inhibitors improve markers for renal and cardiovascular outcomes in patients with and without type 2 diabetes (T2D). To assess whether individual differences in plasma drug exposure can explain inter-individual response variation, we… read more here.
Keywords: exposure response; dapagliflozin empagliflozin; hemodynamics; glucose cotransporter ... See more keywords